At a time when the obesity epidemic continues to affect millions in the UK and worldwide, pharmaceutical innovation and clinical services have moved decisively toward GLP-1 weight loss in the UK and related therapies. This article sets out the public health picture, the role of Wegovy and Mounjaro as NICE-approved options where criteria are met, and how private weight management in 2026 can complement NHS pathways.
The Obesity Epidemic
The obesity epidemic and health risks
Excess weight increases the risk of a number of medical conditions, such as high blood pressure, high cholesterol, heart disease and some cancers. Obesity is also associated with reduced fertility, an increase in mental health problems and numerous joint and mobility problems.